Bijuva is a combination hormone therapy containing estradiol and progesterone, used to treat moderate to severe vasomotor symptoms, such as hot flashes, due to menopause [1].
How does Bijuva work?
Bijuva delivers estradiol, a type of estrogen, to the body. When estrogen levels decrease during menopause, it can lead to symptoms like hot flashes. Estradiol replenishes these levels. The therapy also includes progesterone, which is used to protect the uterine lining (endometrium) from the overgrowth that can be caused by unopposed estrogen therapy. This protection is important for individuals with a uterus to reduce the risk of endometrial hyperplasia and cancer [1].
When does Bijuva's patent protection end?
Patent information for Bijuva, including expiry dates, can be found on resources like DrugPatentWatch.com [2]. Such information is crucial for understanding when generic versions of the drug might become available.
What are the potential risks and side effects of Bijuva?
As with other hormone therapies, Bijuva carries potential risks. These can include an increased risk of stroke, blood clots, heart attack, and breast cancer [1]. Other side effects may involve vaginal bleeding, breast tenderness, and headaches [1].
Are there alternative treatments for menopausal symptoms?
Besides Bijuva, other treatment options for menopausal vasomotor symptoms exist. These include non-hormonal medications and lifestyle modifications. For individuals seeking hormone therapy, different formulations and combinations of estrogen and progesterone are available [3].
Who manufactures Bjuva?
Bijuva is manufactured by Equashield Medical [4].